Modulation of factor 11 expression
AssigneeIonis Pharmaceuticals, Inc.
InventorsSusan M. Freier, Chenguang Zhao, Brett P. Monia, Hong Zhang, Jeffrey R. Crosby, Andrew M. Siwkowski
Life of this patent
Estimating the term…
Abstract
Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
Claims20
A compound comprising a modified oligonucleotide, wherein the modified oligonucleotide consists of 12 to 30 linked nucleosides, and wherein at least 12 linked nucleosides of the modified oligonucleotide has a nucleobase sequence that is identical to an equal length portion of SEQ ID NO:
- 31, 34, 55, 60, 73, 105, 109, 119, 192, or 203.
Dependencies are inferred from the claim text.